254 related articles for article (PubMed ID: 22156549)
21. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene.
Ben-Neriah Y; Daley GQ; Mes-Masson AM; Witte ON; Baltimore D
Science; 1986 Jul; 233(4760):212-4. PubMed ID: 3460176
[TBL] [Abstract][Full Text] [Related]
22. Myeloproliferative disorders.
Meier B; Burton JH
Emerg Med Clin North Am; 2014 Aug; 32(3):597-612. PubMed ID: 25060252
[TBL] [Abstract][Full Text] [Related]
23. The Philadelphia chromosome in leukemogenesis.
Kang ZJ; Liu YF; Xu LZ; Long ZJ; Huang D; Yang Y; Liu B; Feng JX; Pan YJ; Yan JS; Liu Q
Chin J Cancer; 2016 May; 35():48. PubMed ID: 27233483
[TBL] [Abstract][Full Text] [Related]
24. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
Baccarani M; Deininger MW; Rosti G; Hochhaus A; Soverini S; Apperley JF; Cervantes F; Clark RE; Cortes JE; Guilhot F; Hjorth-Hansen H; Hughes TP; Kantarjian HM; Kim DW; Larson RA; Lipton JH; Mahon FX; Martinelli G; Mayer J; Müller MC; Niederwieser D; Pane F; Radich JP; Rousselot P; Saglio G; Saußele S; Schiffer C; Silver R; Simonsson B; Steegmann JL; Goldman JM; Hehlmann R
Blood; 2013 Aug; 122(6):872-84. PubMed ID: 23803709
[TBL] [Abstract][Full Text] [Related]
25. Targeting of BCR-ABL: Lessons learned from BCR-ABL inhibition.
Lin X; Qureshi MZ; Attar R; Khalid S; Tahir F; Yaqub A; Aslam A; Yaylim I; De Carlos Back LK; Farooqi AA; Ismail M
Cell Mol Biol (Noisy-le-grand); 2016 Oct; 62(12):129-137. PubMed ID: 27894413
[TBL] [Abstract][Full Text] [Related]
26. The function of BCR/ABL and related proto-oncogenes.
Gotoh A; Broxmeyer HE
Curr Opin Hematol; 1997 Jan; 4(1):3-11. PubMed ID: 9050373
[TBL] [Abstract][Full Text] [Related]
27. BCR-ABL gene variants.
Melo JV
Baillieres Clin Haematol; 1997 Jun; 10(2):203-22. PubMed ID: 9376660
[TBL] [Abstract][Full Text] [Related]
28. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Thompson PA; Burger JA
Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
[TBL] [Abstract][Full Text] [Related]
29. Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia.
Heisterkamp N; Stephenson JR; Groffen J; Hansen PF; de Klein A; Bartram CR; Grosveld G
Nature; 1983 Nov 17-23; 306(5940):239-42. PubMed ID: 6316147
[TBL] [Abstract][Full Text] [Related]
30. Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome.
Stam K; Heisterkamp N; Grosveld G; de Klein A; Verma RS; Coleman M; Dosik H; Groffen J
N Engl J Med; 1985 Dec; 313(23):1429-33. PubMed ID: 3864009
[TBL] [Abstract][Full Text] [Related]
31. Molecular biology of chronic myeloid leukemia.
Maru Y
Cancer Sci; 2012 Sep; 103(9):1601-10. PubMed ID: 22632137
[TBL] [Abstract][Full Text] [Related]
32. BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates P160 BCR on tyrosine predominantly within the first BCR exon.
Liu J; Campbell M; Guo JQ; Lu D; Xian YM; Andersson BS; Arlinghaus RB
Oncogene; 1993 Jan; 8(1):101-9. PubMed ID: 8423987
[TBL] [Abstract][Full Text] [Related]
33. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells.
Skorski T; Kanakaraj P; Nieborowska-Skorska M; Ratajczak MZ; Wen SC; Zon G; Gewirtz AM; Perussia B; Calabretta B
Blood; 1995 Jul; 86(2):726-36. PubMed ID: 7606002
[TBL] [Abstract][Full Text] [Related]
34. Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate.
Anafi M; Gazit A; Zehavi A; Ben-Neriah Y; Levitzki A
Blood; 1993 Dec; 82(12):3524-9. PubMed ID: 7505115
[TBL] [Abstract][Full Text] [Related]
35. Pim kinases in cancer: diagnostic, prognostic and treatment opportunities.
Blanco-Aparicio C; Carnero A
Biochem Pharmacol; 2013 Mar; 85(5):629-643. PubMed ID: 23041228
[TBL] [Abstract][Full Text] [Related]
36. Chronic myelogenous leukemia: a review.
Cortes JE; Talpaz M; Kantarjian H
Am J Med; 1996 May; 100(5):555-70. PubMed ID: 8644769
[TBL] [Abstract][Full Text] [Related]
37. Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy.
Rossari F; Minutolo F; Orciuolo E
J Hematol Oncol; 2018 Jun; 11(1):84. PubMed ID: 29925402
[TBL] [Abstract][Full Text] [Related]
38. BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia.
Loscocco F; Visani G; Galimberti S; Curti A; Isidori A
Front Oncol; 2019; 9():939. PubMed ID: 31612105
[TBL] [Abstract][Full Text] [Related]
39. Leukemia stem cells: the root of chronic myeloid leukemia.
Zhou H; Xu R
Protein Cell; 2015 Jun; 6(6):403-12. PubMed ID: 25749979
[TBL] [Abstract][Full Text] [Related]
40. Philadelphia chromosome-like acute lymphoblastic leukemia.
Tasian SK; Loh ML; Hunger SP
Blood; 2017 Nov; 130(19):2064-2072. PubMed ID: 28972016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
